Northern Trust’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-90,346
| Closed | -$269K | – | 4242 |
|
|
2016
Q3 | $269K | Sell |
90,346
-19
| -0% | -$33 | ﹤0.01% | 3653 |
|
|
2016
Q2 | $135K | Sell |
90,365
-235,065
| -72% | -$538K | ﹤0.01% | 3813 |
|
|
2016
Q1 | $1.43M | Sell |
325,430
-809
| -0.2% | -$5.01K | ﹤0.01% | 3135 |
|
|
2015
Q4 | $3.29M | Buy |
326,239
+5,361
| +2% | +$64.5K | ﹤0.01% | 2735 |
|
|
2015
Q3 | $4.36M | Sell |
320,878
-33,902
| -10% | -$604K | ﹤0.01% | 2526 |
|
|
2015
Q2 | $6.73M | Buy |
354,780
+2,605
| +0.7% | +$56.4K | ﹤0.01% | 2322 |
|
|
2015
Q1 | $9.22M | Buy |
352,175
+1,318
| +0.4% | +$33.5K | ﹤0.01% | 2121 |
|
|
2014
Q4 | $7.35M | Sell |
350,857
-18,804
| -5% | -$474K | ﹤0.01% | 2247 |
|
|
2014
Q3 | $12.3M | Buy |
369,661
+21,061
| +6% | +$654K | ﹤0.01% | 1877 |
|
|
2014
Q2 | $11.2M | Sell |
348,600
-52,389
| -13% | -$1.95M | ﹤0.01% | 1956 |
|
|
2014
Q1 | $18.5M | Sell |
400,989
-8,917
| -2% | -$523K | 0.01% | 1635 |
|
|
2013
Q4 | $29.1M | Sell |
409,906
-5,087
| -1% | -$389K | 0.01% | 1201 |
|
|
2013
Q3 | $35.6M | Buy |
414,993
+13,450
| +3% | +$1.14M | 0.01% | 946 |
|
|
2013
Q2 | $25.4M | Buy |
+401,543
| New | +$21.3M | 0.01% | 1192 |
|
Northern Trust's AEGR Position: Q4 2016 in Review
Northern Trust sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 90,346 shares — an estimated $269K sold.
Northern Trust first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $35.6M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Northern Trust reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Northern Trust sold 90,346 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $269K.
- Northern Trust first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Northern Trust's Aegerion Pharmaceuticals position peaked at $35.6M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Northern Trust's 13F filing for Q4 2016, filed 13 Feb 2017.